Miguel Perales, MD
Following allogeneic hematopoietic stem cell transplant (HSCT), the recently FDA-approved regimen letermovir (Prevymis) is highly recommended for high-risk patients with cytomegalovirus (CMV) infection, according to Miguel Perales, MD.
The phase III trial that led to the November 2017 approval randomized 495 patients with baseline undetectable plasma CMV DNA in a 2:1 ratio to receive letermovir once daily versus placebo following HSCT. The results showed that 37.5% of patients treated with letermovir developed CMV by week 24 compared with 60.6% of those treated with placebo (P
<.0001). Additionally, letermovir was associated with a lower mortality rate of 12% versus 17% in the placebo arm at 24 weeks.
... to read the full story